RxDoctor Payments Data

Callie Davidson

Family · Pueblo, CONPI 1982289625

Payments from drug & device makers

$3,304in general payments, 2019–2025

Across 164 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$652
  • Novo Nordisk$298
  • Pfizer$278
  • Scilex Pharmaceuticals Inc.$273
  • Otsuka America Pharmaceutical, Inc.$202
  • Exact Sciences$149
  • plus $1K from 31 others

What the payments were for

  • Food & beverage$3,304100%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,304 in reported general payments places this provider in the 90th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$82,136
Medicare patients
83
Services billed
1,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl113$91,282
Buprenorphine109$28,774
OzempicSemaglutide23$24,211
Xtampza ErOxycodone Myristate53$22,027
JardianceEmpagliflozin15$14,391
LinzessLinaclotide25$13,439
MovantikNaloxegol Oxalate24$9,585
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen281$8,826
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen240$8,679
Oxycodone Hcl398$6,769
Repatha SureclickEvolocumab11$6,359
Lidocaine43$6,079
Morphine Sulfate ErMorphine Sulfate71$5,172
Gabapentin112$3,577
Pregabalin181$2,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$91$113,309166 claims
Novo NordiskOzempic$298$24,21123 claims
AbbVieLinzess$652$13,43925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,182 family providers in Colorado.

Other family in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →